Enhancement of the IFN-β-induced host signature informs repurposed drugs for COVID-19

Enhancement of the IFN-β-induced host signature informs repurposed drugs for COVID-19

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a causative agent for the outbreak of coronavirus disease 2019 (COVID-19). This global pandemic is now calling for efforts to develop more effective COVID-19 therapies. Here we use a host-directed approach, which focuses on cellular res...

Full description

Bibliographic Details
Main Authors: Chen-Tsung Huang, Tai-Ling Chao, Han-Chieh Kao, Yu-Hao Pang, Wen-Hau Lee, Chiao-Hui Hsieh, Sui-Yuan Chang, Hsuan-Cheng Huang, Hsueh-Fen Juan
Format: Article
Language:English
Published: Elsevier 2020-12-01
Series:Heliyon
Subjects:
Systems biology
COVID-19
Host-directed therapy
Type I interferon
Drug repurposing
Bioinformatics
Online Access:http://www.sciencedirect.com/science/article/pii/S2405844020324890

Similar Items

Similar Items